ASSESSING THE DISTRIBUTION OF SELF-PAYING INNOVATIVE ONCOLOGY MEDICINE AMONG CANCER PATIENTS
Background: Innovative oncology medicines offer advanced cancer treatment but often come with high costs, limiting access through public healthcare funding.
Aims: This study examines the distribution of self-paying innovative cancer drugs among patients in Malaysian public hospitals.
Methods: Using oncology pharmacy records from 2017 to 2020, 157 patient samples were collected, constrained by COVID-19 restrictions.
Results: The average patient age was 57 years (SD: 11.47), with a predominance of females (73.9%) and Chinese ethnicity (48%). Breast cancer was the most common diagnosis (47%), followed by lung (17%) and colon cancer (10%). Frequently prescribed drugs included Trastuzumab, Palbociclib, Osimertinib, Cetuximab, and Bevacizumab, most of which are listed in the Ministry of Health’s formulary of listed anticancer drugs (FLAD). Patients paid an average annual cost of MYR 16,233.90 (SD: 20,424.67) for FLAD and MYR 11,239.75 (SD: 122,793.50) for non-FLAD.
Conclusion: The study highlights that out-of-pocket payments are the primary funding source for these treatments, posing significant financial burdens and potential long-term economic strain on cancer patients in Malaysia.
Keywords: FLAD, Funding Mechanism, Innovative Oncology Medicine
Bygrave, A., Whittaker, K., Paul, C., Fradgley, E.A., Varlow, M. and Aranda, S., 2021. Australian experiences of out-of-pocket costs and financial burden following a cancer diagnosis: A systematic review. International Journal of Environmental Research and Public Health,18(5). https://doi.org/10.3390/ijerph18052422.
Carrera, P.M., Kantarjian, H.M. and Blinder, V.S., 2018. The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA: A Cancer Journal for Clinicians, 68(2), pp.153–165. https://doi.org/10.3322/caac.21443.
Cochran, W.G., 1977. Sampling Techniques. 2nd ed. New York: John Wiley & Sons, Inc.
Cortes, J. et al., 2020. Enhancing global access to cancer medicines. CA: A Cancer Journal for Clinicians, 70(2), pp.105–124. https://doi.org/10.3322/caac.21597
Coumoundouros, C., Ould Brahim, L., Lambert, S.D. and McCusker, J., 2019. The direct and indirect financial costs of informal cancer care: A scoping review. Health & Social Care in the Community, 27(5), pp.e622–e636. https://doi.org/10.1111/hsc.12808.
Debela, D.T., Muzazu, S.G., Heraro, K.D., et al., 2021. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Medicine, 9. https://doi.org/10.1177/20503121211034366.
Department of Statistics Malaysia, 2022. Key Findings Population and Housing Census of Malaysia 2020. [online] Available at: https://cloud.stats.gov.my/index.php/s/BG11nZfaBh09RaX#pdfviewer.
Donkor, A. et al., 2022. Financial toxicity of cancer care in low- and middle-income countries: A systematic review and meta-analysis. Supportive Care in Cancer. https://doi.org/10.1007/s00520-022-07044-z.
Fnu, N. et al., 2022. Cancer-related costs, the resulting financial impact and coping strategies among cancer survivors living in a setting with a pluralistic health system: A qualitative study. Ecancermedicalscience, 16, p.1449. https://doi.org/10.3332/ecancer.2022.1449.
Goh, B.-C. and Lim, J.F.-Y., 2020. Cancer drugs in Asian populations: Availability, accessibility, and affordability. The Cancer Journal, 26(4), pp.323–329.
International Agency for Research on Cancer, 2021. Burden of Cancer Population Fact Sheets: Malaysia. [online] Available at: https://gco.iarc.fr/today/data/factsheets/populations/458-malaysia-fact-sheets.pdf.
IQVIA, 2019. The Global Use of Medicine in 2019 and Outlook to 2023 – Forecasts and Areas to Watch. [online] Available at: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf.
IQVIA (2021) MIDAS: Malaysia chemotherapy retail prices (private sector), 2021 [Dataset]. Durham, NC: IQVIA. Available at: https://www.iqvia.com/ (Accessed: 24 October 2021).
Leighl, N.B., Nirmalakumar, S., Ezeife, D.A. and Gyawali, B., 2021. An arm and a leg: The rising cost of cancer drugs and impact on access. ASCO Educational Book, (41), pp.e1–e12. https://doi.org/10.1200/edbk_100028.
Malaysia National Cancer Registry, 2019. Malaysia National Cancer Registry Report (MNCR) 2012–2016. [online] Available at: http://nci.moh.gov.my.
Ministry of Health Malaysia, 2017. National Strategic Plan for Cancer Control Programme 2016–2020. Putrajaya: Ministry of Health Malaysia.
Ministry of Health Malaysia, 2018. Malaysian Study on Cancer Survival (MySCan). [online] Available at: http://nci.moh.gov.my/index.php/ms/main-menu-2/laporan.
Ministry of Health Malaysia, 2021. National Strategic Plan for Cancer Control Programme 2021–2025. Putrajaya: Ministry of Health Malaysia.
Moye-Holz, D., van Dijk, J.P., Reijneveld, S.A. and Hogerzeil, H.V., 2019. The impact of price negotiations on public procurement prices and access to 8 innovative cancer medicines in a middle-income country: The case of Mexico. Value in Health Regional Issues, 20, pp.129–135. https://doi.org/10.1016/j.vhri.2019.04.006.
Ngan, T.T., Van Minh, H., Donnelly, M. and O’Neill, C., 2021. Financial toxicity due to breast cancer treatment in low- and middle-income countries: Evidence from Vietnam. Supportive Care in Cancer, 29(11), pp.6325–6333. https://doi.org/10.1007/s00520-021-06210-z.
Nik Ab Kadir, M.N. et al., 2023. myBeST—A web-based survival prognostic tool for women with breast cancer in Malaysia: Development process and preliminary validation study. International Journal of Environmental Research and Public Health, 20(4), p.2985. https://www.mdpi.com/1660-4601/20/4/2985.
O’Reilly, D. et al., 2023. Cost and public reimbursement of cancer medicines in the UK and the Republic of Ireland. Irish Journal of Medical Science, 192(2), pp.541–548. https://doi.org/10.1007/s11845-022-02990-3.
Pucci, C., Martinelli, C. and Ciofani, G., 2019. Innovative approaches for cancer treatment: Current perspectives and new challenges. Ecancermedicalscience, 13, p.961. https://doi.org/10.3332/ecancer.2019.961.
Raman, S. et al., 2022. Household catastrophic health expenditure from oral potentially malignant disorders and oral cancer in public healthcare of Malaysia. Asian Pacific Journal of Cancer Prevention, 23(5), pp.1611–1618. https://doi.org/10.31557/apjcp.2022.23.5.1611.
Rothenberg, M.L., McCarthy, J.J. and Holmes, P., 2020. Price, cost, and value of cancer medicines: A pharmaceutical industry perspective. The Cancer Journal, 26(4), pp.281–286. https://doi.org/10.1097/PPO.0000000000000455.
Tan, M.M. et al., 2023. Breast cancer and breast cancer screening use—beliefs and behaviours in a nationwide study in Malaysia. BMC Public Health, 23(1), p.1319. https://doi.org/10.1186/s12889-023-16227-0.
Tan, S.C. et al., 2023. Challenges and strategies for improving access to cancer drugs in Malaysia: Summary of opinions expressed at the 2nd MACR International Scientific Conference 2022. Cancer Management and Research, 15, pp.851–862. https://doi.org/10.2147/CMAR.S420890.
Ting, C.Y. et al., 2020. Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country. Supportive Care in Cancer, 28(4), pp.1703–1715. https://doi.org/10.1007/s00520-019-04975-y.
Tucker-Seeley, R.D., 2023. Financial toxicity: A barrier to achieving health equity in cancer care. Journal of the American College of Radiology, 20(1), pp.37–39. https://doi.org/10.1016/j.jacr.2022.12.004.
Zheng, Z. et al., 2020. Financial hardship, healthcare utilization, and health among U.S. cancer survivors. American Journal of Preventive Medicine, 59(1), pp.68–78. https://doi.org/10.1016/j.amepre.2020.02.016.
Copyright (c) 2025 Mohd Redhuan Dzulkipli, Asrul Akmal Shafie, Siti Noorsuriani Maon, Azuana Ramli, Abdul Haniff Mohammad Yahaya, See Wan Ho, Nor Ilham Ainaa Muhsin, Azmi Nor Mohd Farez Ahmat
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. As an author you (or your employer or institution) may do the following:
- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a ‘work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author's personal use or for company use, provided that the source and the copyright notice are indicated.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal.
2. Requests from third parties
Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use.
3. Author Online Use
- Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from JAKI;
- Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author's personal web site or the servers of the author's institution or company in connection with the author's teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
